VEGFA and hereditary hemorrhagic telangiectasia: Importantly, the anti-VEGF inhibitor bevacizumab reduces the risk of cardiac disease in HHT patients with liver vascular malformations and reduces nosebleeds from nasal telangiectases (101, 102), making VEGF one of the most significant drug targets for patient therapy, despite the risks of significant side effects.